

Einar Bjornsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10808558/publications.pdf>

Version: 2024-02-01

63
papers

7,222
citations

66234

42
h-index

110170

64
g-index

66
all docs

66
docs citations

66
times ranked

7180
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome and prognostic markers in severe drug-induced liver disease. <i>Hepatology</i> , 2005, 42, 481-489.	3.6	509
2	Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. <i>Hepatology</i> , 2010, 51, 2040-2048.	3.6	405
3	Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals. <i>Hepatology</i> , 2008, 47, 2003-2009.	3.6	343
4	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , 2013, 45, 670-675.	9.4	339
5	Risk Factors for Idiosyncratic Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2010, 138, 2246-2259.	0.6	295
6	The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. <i>Hepatology</i> , 2011, 54, 931-939.	3.6	279
7	Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. <i>Journal of Hepatology</i> , 2012, 56, 374-380.	1.8	264
8	Immunoglobulin G4 associated cholangitis: Description of an emerging clinical entity based on review of the literature. <i>Hepatology</i> , 2007, 45, 1547-1554.	3.6	224
9	Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. <i>Hepatology</i> , 2010, 51, 615-620.	3.6	223
10	Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. <i>Nature Genetics</i> , 2011, 43, 17-19.	9.4	221
11	Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: A nationwide study. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1232-1240.	0.6	200
12	Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. <i>Journal of Hepatology</i> , 2012, 57, 366-375.	1.8	196
13	Hepatotoxicity by Drugs: The Most Common Implicated Agents. <i>International Journal of Molecular Sciences</i> , 2016, 17, 224.	1.8	195
14	Dominant Strictures in Patients with Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2004, 99, 502-508.	0.2	164
15	Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in sweden. <i>Hepatology</i> , 2010, 52, 571-577.	3.6	164
16	Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at <i>GPR35</i> and <i>TCF4</i> . <i>Hepatology</i> , 2013, 58, 1074-1083.	3.6	150
17	Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in Vigibase, c. <i>Drug Safety</i> , 2010, 33, 503-522.	1.4	142
18	Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , 2011, 43, 309-313.	0.4	138

#	ARTICLE	IF	CITATIONS
19	Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. <i>Journal of Hepatology</i> , 1998, 28, 426-432.	1.8	130
20	The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. <i>Journal of Hepatology</i> , 2009, 50, 511-517.	1.8	129
21	Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 1095-1101.	0.6	125
22	Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: Impact of structured management on recidivism. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 206-216.	0.6	120
23	Primary Sclerosing Cholangitis Associated with Elevated ImmunoglobulinG4: Clinical Characteristics and Response to Therapy. <i>American Journal of Therapeutics</i> , 2011, 18, 198-205.	0.5	119
24	Drug-induced liver injury: a clinical update. <i>Current Opinion in Gastroenterology</i> , 2010, 26, 222-226.	1.0	110
25	Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for <i>IL2, REL</i> , and <i>CARD9</i> . <i>Hepatology</i> , 2011, 53, 1977-1985.	3.6	110
26	Gastrointestinal symptoms in patients with liver cirrhosis: Associations with nutritional status and health-related quality of life. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 1464-1472.	0.6	109
27	Drug-induced liver injury: Hyâ€™s rule revisited. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 521-528.	2.3	103
28	Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis. <i>Liver International</i> , 2007, 27, 1194-1201.	1.9	90
29	Coronary Artery Disease in Patients with Liver Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 467-475.	1.1	78
30	Altered postprandial glucose, insulin, leptin, and ghrelin in liver cirrhosis: correlations with energy intake and resting energy expenditure. <i>American Journal of Clinical Nutrition</i> , 2007, 85, 808-815.	2.2	74
31	Clinical characteristics and prognostic markers in disulfiram-induced liver injury. <i>Journal of Hepatology</i> , 2006, 44, 791-797.	1.8	72
32	Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. <i>Journal of Hepatology</i> , 2009, 50, 388-393.	1.8	72
33	Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 457-467.	0.6	72
34	Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. <i>Liver International</i> , 2012, 32, 441-448.	1.9	72
35	Epidemiology and Risk Factors for Idiosyncratic Drug-Induced Liver Injury. <i>Seminars in Liver Disease</i> , 2014, 34, 115-122.	1.8	64
36	Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 1090-1094.	0.6	60

#	ARTICLE	IF	CITATIONS
37	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253.	2.3	58
38	Gut Transit Is Associated With Gastrointestinal Symptoms and Gut Hormone Profile in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 346-352.	2.4	57
39	Patients With Typical Laboratory Features of Autoimmune Hepatitis Rarely Need a Liver Biopsy for Diagnosis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 57-63.	2.4	51
40	Factors Related to Fatigue in Patients With Cirrhosis Before and After Liver Transplantation. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 174-181.e1.	2.4	48
41	Non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 1023-1030.	0.6	45
42	The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , 2014, 46, 903-908.	0.4	42
43	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Cut</i> , 2018, 67, 1517-1524.	6.1	42
44	Fatigue is not a specific symptom in patients with primary biliary cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 351-357.	0.8	41
45	Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. <i>Liver International</i> , 2014, 34, 1488-1495.	1.9	41
46	Inadequate use of proton-pump inhibitors in patients with liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 512-518.	0.8	36
47	Immunoglobulin G4-associated cholangitis. <i>Current Opinion in Gastroenterology</i> , 2008, 24, 389-394.	1.0	36
48	Prevalence of pre-transplant electrocardiographic abnormalities and post-transplant cardiac events in patients with liver cirrhosis. <i>BMC Gastroenterology</i> , 2014, 14, 65.	0.8	36
49	The Natural History of Drug-Induced Liver Injury. <i>Seminars in Liver Disease</i> , 2009, 29, 357-363.	1.8	29
50	Effects of Duodenal Lipids on Gastric Sensitivity and Relaxation in Patients with Ulcer-Like and Dysmotility-Like Dyspepsia. <i>Digestion</i> , 2003, 67, 209-217.	1.2	27
51	Pregabalin as a probable cause of acute liver injury. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 1049.	0.8	27
52	Type and etiology of liver cirrhosis are not related to the presence of hepatic encephalopathy or health-related quality of life: a cross-sectional study. <i>BMC Gastroenterology</i> , 2008, 8, 46.	0.8	26
53	Hepatic encephalopathy is related to anemia and fat-free mass depletion in liver transplant candidates with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 577-584.	0.6	24
54	Pre-Transplant Renal Impairment Predicts Posttransplant Cardiac Events in Patients With Liver Cirrhosis. <i>Transplantation</i> , 2014, 98, 107-114.	0.5	23

#	ARTICLE	IF	CITATIONS
55	Coronary artery disease in liver cirrhosis: Does the aetiology of liver disease matter?. Journal of Hepatology, 2009, 51, 962-963.	1.8	19
56	Hepatic encephalopathy in patients with liver cirrhosis: Is there a role of malnutrition?. World Journal of Gastroenterology, 2008, 14, 3438.	1.4	18
57	Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study. Journal of Hepatology, 2022, 76, 832-840.	1.8	16
58	Gastrointestinal symptoms in patients with cirrhosis: a longitudinal study before and after liver transplantation. Scandinavian Journal of Gastroenterology, 2013, 48, 1308-1316.	0.6	15
59	Lactulose treatment for hepatic encephalopathy, gastrointestinal symptoms, and health-related quality of life. Hepatology, 2007, 46, 949-950.	3.6	13
60	Abstinence in patients with alcoholic liver cirrhosis: A follow-up study. Hepatology Research, 2008, 38, 869-876.	1.8	12
61	Sclerosing cholangitis. Current Opinion in Gastroenterology, 2003, 19, 270-275.	1.0	7
62	Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis. Quality of Life Research, 2016, 25, 947-957.	1.5	5
63	Cognitive dysfunction in liver cirrhosis: does hepatitis C virus play a role?. Journal of Gastroenterology, 2008, 43, 248-248.	2.3	1